UroGen Pharma Ltd. (URGN) financial statements (2021 and earlier)

Company profile

Business Address 9 HA'TA'ASIYA ST
RA'ANANA, 4365007
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments147101
Cash and cash equivalents50101
Short-term investments97 
Restricted cash and investments10
Other undisclosed current assets11
Total current assets:149102
Noncurrent Assets
Operating lease, right-of-use asset4
Property, plant and equipment11
Long-term investments and receivables49 
Long-term investments49 
Restricted cash and investments00
Other noncurrent assets00
Total noncurrent assets:541
TOTAL ASSETS:202104
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:119
Accounts payable54
Accrued liabilities12
Other undisclosed accounts payable and accrued liabilities62
Debt2 
Other liabilities2 
Other undisclosed current liabilities55
Total current liabilities:1913
Noncurrent Liabilities
Long-term debt and lease obligation3 
Operating lease, liability3
Total noncurrent liabilities:3 
Total liabilities:2213
Stockholders' equity
Stockholders' equity attributable to parent18090
Common stock00
Additional paid in capital408213
Accumulated other comprehensive income0 
Accumulated deficit(228)(123)
Total stockholders' equity:18090
TOTAL LIABILITIES AND EQUITY:202104

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Revenues01
Sublease income0
Cost of revenue (2)
Other undisclosed gross profit(0) 
Gross profit:0(1)
Operating expenses(109)(77)
Operating loss:(109)(77)
Nonoperating expense
(Other Nonoperating expense)
(0) 
Loss from continuing operations before equity method investments, income taxes:(110)(77)
Other undisclosed income from continuing operations before income taxes52
Loss from continuing operations before income taxes:(105)(76)
Income tax expense (0)
Net loss available to common stockholders, diluted:(105)(76)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(105)(76)
Other comprehensive income0 
Comprehensive loss, net of tax, attributable to parent:(105)(76)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: